BioTree, a trailblazer in China's metabolomics sector, has recently declared the successful closure of its Series B funding round, raising close to 100 million RMB. This financing endeavor was singularly spearheaded by CSC Capital, with continued support from existing investor Qiming Venture Partners.

The newly acquired funds will be strategically allocated to advance research and development in multi-omics and AI for Science. Additionally, they will fuel the creation of novel products, the establishment of a multi-omics and AI mass spectrometry capacity center in Zhejiang, and the setting up of an overseas headquarters in Singapore, along with laboratories in Europe and the United States. The overarching objective is to foster the global implementation of these technologies across diverse domains.

Since its inception in Shanghai in 2012, BioTree has been at the forefront of applying cutting-edge mass spectrometry technologies. The company has garnered multiple qualification certifications and secured over a hundred patents and software copyrights, cementing its technical prowess as a leader in the industry. Its operations span both domestic and international markets, having catered to numerous organizations and forged multiple collaborative achievements.